We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
14/4/2023 01:01 | Steady support from Octopus ... | piedro | |
26/3/2023 17:23 | Yep Piedro, very impressive contribution - great graph! | maddox | |
25/3/2023 10:55 | This is a chart I like that illustrates the Barfield era ... | piedro | |
22/3/2023 23:49 | Thanks Piedro, What your graph nicely illustrates is the growing revenue from North America. They have now established sufficient scale to compete for top-tier contracts - if successful this will further propel growth over the next few years. | maddox | |
21/3/2023 11:19 | No Dividend but excellent results and in-line with analyst consensus forecasts: Service fee revenue +24% (in-line with analyst consensus forecasts) Gross profit +22% Gross margin +40.7% Adj. EBITDA +11.5% Adj. eps 42.6p (consensus 40.1p) Order book +23% ADAMAS acquisition looks to have bedded-in well and the outlook looks highly positive. So, we have a strongly growing company in a growing market - but growing ahead of that market growth. Postscript: Shares opened at 1020p rose 40p to 1060p but then faltered and dropped down 23p at 997p. interesting reaction to strong results indicative of a risk-off market rather than specific to ERGO. | maddox | |
29/1/2023 11:03 | Richard Barfield has been extremely impressive so very grateful for his contribution to the transformation of ERGO. He will be a difficult act to follow. However, the strategy is set and the execution going exceedingly well so his contribution will be sustained. He has a c. 1m options on shares which is equivalent to about 2% of ERGO, so we'll have to see what he does with these. Hopefully he'll retain a sizeable holding in ERGO and an informal, if not formal, advisory role in future. Apart from that I like to express my thanks as a shareholder and wish him a very long and very, very happy retirement. If you share my sentiments please give this post a thumbs-up. Cheers Maddox | maddox | |
27/1/2023 10:19 | better he retired then jumped ship to another company. IMHO. | mfhmfh | |
26/1/2023 16:00 | "Richard Barfield retiring is a big negative ..." LOL, no doubt conspiracy theories abound "he sold a large part of his shareholding last year - I took his cue and sold out then" So what?. He cashed in 125,000 10p options and has plenty more | piedro | |
26/1/2023 15:11 | RB's retirement a very big negative sign. he sold a large part of his shareholding last year - I took his cue and sold out then | qvg | |
26/1/2023 12:28 | Richard Barfield retiring is a big negative on the stock unfortunately. In short he transformed his previous company and then Ergomed - check the share price after he was appointed .The retirement expectation was on the wall when the deputy CFO was appointed. I sold half before the announcement and the other half yesterday. | ihatemms | |
26/1/2023 10:56 | Positive trading update. But no move in share price. Likely due to the still high PE ratio in an era where PEs have reduced a lot. | fegger | |
14/10/2022 15:34 | Octopus holdings {from my records} | piedro | |
10/10/2022 11:06 | PrimeVigilance@Prime EVENT – Greetings from Tokyo! We are so pleased to be a first-time exhibitor at the DIA Japan Annual Meeting. If you are attending, look up Booth #19 and stop by to meet our team from our regional hub in Tokyo. | piedro | |
27/9/2022 16:06 | It is a service business Productivity improvements are probably limited | phillis | |
27/9/2022 12:19 | Updated chart ... - that is what I wanted to see: cost growth moderated | piedro | |
27/9/2022 09:46 | Another very impressive web-cast today. | ihatemms | |
26/7/2022 11:32 | Ergomed cheers 'very strong' performance in first half of 2022 | piedro | |
26/7/2022 09:54 | Excellent update for interims and H2 outlook particularly order book. glad I topped up recently. | adorling | |
26/7/2022 09:47 | Business as usual update, but can they keep costs under control? | piedro | |
25/7/2022 11:22 | let's see what tomorrow brings | mfhmfh |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions